So far, preparations are being made to use the vaccine that eradicates poliovirus to prevent coronavirus infection proving incurable. Although globally researchers have suggested the use of the ole vaccine for polio, Indian scientists have shown a very cautious approach to this advice. They have recognized that this vaccine should be tested for use in the treatment of coronavirus (Covid-19), but they also hoped that it would probably provide limited protection against infection.
Actually, it is being said that it takes at least a year to prepare any vaccine, especially for Kovid-19. Scientists say that a safe and effective vaccine is already in place for immediate relief against this virus. These vaccines also include the Oral Polio Vaccine (OPV) and the anti-tuberculosis Bacillus Calametegurin (BCG). Both these vaccines are already part of the immunization campaign for Indian children. A medical test of OPV is worth conducting, said Ram Vishwakarma, director of the CSIR-Indian Institute of Integrative Medicine (CSIR-IIIM), Jammu. Vishwakarma said about a study by an international research team published in a science journal last week, “If OPV can protect people against the SARS-Cove-2 virus, it should be tested.” Explain that two international scientists of the US, Shyamsundram Kottli and Robert Gallo were also included in this international research team. Gallo, an internationally renowned virologist, has been instrumental in the discovery of the HIV virus that spreads AIDS.
He noted that the vaccine used to prevent poliomyelitis infection has been in use since the 1950s and has been found to be an antidote to many other viral infections. But he also said, in general, innate immunity can be enhanced by applying the vaccine and OPV can provide temporary protection against corona infection accordingly. According to Vishwakarma, the idea proposed by Gallo is based on a strong scientific hypothesis. But we do not know what is going to happen in the end, because it has many stages (of corona infection). The polio vaccine may help patients with mild symptoms in the early stage, but may not be effective on severe patients.
Another immunologist, Satyajit Rath, said, “We should keep in mind that Gallo and his team are not talking about working as an OPV vaccine, which elicits a particular immune response.” Instead, they are talking about giving people a viral infection, any viral infection that will activate the body’s innate antiviral, and inflammatory immunity. This will reduce the chances of any other virus (SARS-Cove-2 or any other) entering the body during that time. Satyajit Rath, a scientist at the National Institute of Immunology (NII), Delhi, further said that this approach might work. To some extent, this is my guess and it is not enough to make it particularly useful. It is a good idea to use already available vaccines. There is scope for some degree of protection. But this will happen only when the two pathogen proteins are of the same sequence.